Hair cosmetic composition containing enzyme-converted sophorae radix extract and method for producing same

Abstract

The present invention relates to a hair cosmetic composition containing an enzyme-converted Sophorae Radix extract, and a method for producing same, and more specifically, to a hair cosmetic composition containing, as an active ingredient, a Sophorae Radix extract in which the content of trifolirhizin, which is the active ingredient in Sophorae Radix, has been increased through an enzyme treatment, that is, a hair cosmetic composition having hair root strengthening, hair growth, and hair loss alleviation effects. Using the hair cosmetic composition comprising an enzyme-converted Sophorae Radix extract as an active ingredient according to the present invention not only promotes hair root strengthening and hair growth by stimulating hair growth factors, but also suppresses hair loss-inducing factors, which shorten the anagen phase and promote transition to the catagen phase, and shortens the telogen phase in an inflammatory environment by exhibiting anti-inflammatory activity, and thus is expected to have excellent hair loss alleviation effects.

Description

Hair cosmetic composition containing enzyme-converted ginseng extract and method for producing the same

[0001] This patent application claims priority to Republic of Korea Patent Application No. 10-2023-0095466, filed with the Korean Intellectual Property Office on July 21, 2023, the disclosure of which is incorporated herein by reference.

[0002] The present invention relates to a hair cosmetic composition containing an enzyme-converted Sophora japonica extract, and a method for producing the same. Specifically, the present invention relates to a hair cosmetic composition containing a Sophora japonica extract having an increased content of trifolirhizin, an effective ingredient in Sophora japonica, through enzyme treatment, as an effective ingredient, that is, a hair cosmetic composition having the effects of strengthening hair roots, growing hair, and alleviating hair loss.

[0003]

[0004] Human hair protects the skin and scalp. Scalp hair, in particular, accounts for approximately 20% of all human hair. It plays a unique role in social and sexual communication, making it a crucial element. However, with recent industrialization and increased exposure to diverse environments, the number of people struggling with hair loss and scalp issues is increasing.

[0005] In the past, most hair loss cases occurred in middle-aged and older people in their 50s and older, but recently, due to excessive use of shampoos and mousses, damage to the hair and scalp from perms, dyeing, and using hair dryers, increased environmental stress, and nutritional imbalances caused by increased intake of processed foods, hair loss is occurring noticeably in younger people in their 20s and 30s as well. In addition to male-pattern baldness, female-pattern baldness is also on the rise. In particular, according to the National Health Review and Assessment Service, the number of people visiting hospitals for hair loss increased from approximately 200,000 in 2014 to approximately 220,000 in 2018, and the Korean Society for Hair Loss Treatment estimates that the potential hair loss population in Korea is 10 million.

[0006] The lifespan of hair is composed of four stages: anagen phase, catagen phase, telogen phase, and exogenous phase, and hair is maintained by repeating these four stages. The hair cycle is determined by the activity cycle of the dermal papilla (DP), with the anagen phase lasting 5-6 years, the catagen phase lasting 2-3 weeks, and the telogen phase lasting approximately 2-3 months. When the final stage of the telogen phase is reached, the telogen phase, in which new hair is naturally generated, begins, and the hair is maintained anew, so hair loss is considered a natural phenomenon for new hair generation. However, alopecia, which is recognized as a hair loss disease, refers to a symptom in which the activity of the dermal papilla stops, resulting in a relatively increased proportion of hair in the telogen phase or no hair regeneration.

[0007] Although research has been conducted on the causes and mechanisms of alopecia, the cause of hair loss has not yet been clearly identified. The main factors that affect hair growth include inhibition of proliferation or decreased function of the dermal papilla related to hair cycle regulation, abnormality of the hair cycle due to androgen action, abnormal changes in the hair cycle due to decreased blood flow to the scalp, anti-hypertensive drugs, mental stress, physical stimulation, and environmental pollution.

[0008] Accordingly, the development of hair loss treatments is progressing worldwide, and various methods such as topical application agents, oral medications, health supplements, gene transplant surgery, hair transplant surgery, and alternative medicine are being implemented as treatment methods for hair loss, but it is known that there is no treatment method or substance that has yet shown satisfactory results.

[0009] In particular, although there are thousands of hair growth products on the market worldwide, there are not many products that are actually recognized by the Hair Growth Society, and currently, only minoxidil and Propecia have been approved by the Food and Drug Administration (FDA) as drugs that promote hair growth. It is known that the topical application of 'minoxidil' or the oral medication 'Propecia (ingredient: finasteride)' can slow down the progression of hair loss to some extent in the early stages of hair loss, but it is difficult to return to normal for hair loss that has already progressed, and side effects such as hair growth in unwanted areas, erectile dysfunction, decreased libido, dizziness, headache, edema, and skin rash may occur. In addition, there is a concern that it may cause birth defects when taken, so there is a problem that it cannot be prescribed to women.

[0010] Moreover, since hair loss prevention and hair growth products are applied directly to the scalp or taken orally, efforts are needed to explore natural ingredients that do not contain chemical substances, extract effective ingredients beneficial to scalp health, and develop products containing these ingredients.

[0011]

[0012] The present inventors have diligently researched and developed a hair cosmetic composition containing as an active ingredient a substance extracted from a natural product free of chemical components. As a result, an enzyme-converted Sophora flavescens extract was produced through enzyme treatment with an increased content of trifolirhizin, an active ingredient in Sophora flavescens, and the enzyme-converted Sophora flavescens extract was elucidated for its effects in strengthening hair roots, promoting hair growth, and alleviating hair loss, thereby completing the present invention.

[0013] Accordingly, the purpose of the present invention is to provide a method for producing an enzyme-converted ginseng extract.

[0014] Another object of the present invention is to provide a hair cosmetic composition for strengthening hair roots, promoting hair growth, or alleviating hair loss, which contains the enzyme-converted ginseng extract as an active ingredient.

[0015] Other objects and advantages of the present invention will become more apparent from the detailed description, claims and drawings below.

[0016]

[0017] The present inventors have conducted extensive research efforts to develop a hair cosmetic composition containing as an active ingredient a substance extracted from a natural source free of chemical components. As a result, an enzyme-converted Sophora flavescens extract was produced with an increased content of trifolirhizin, an active ingredient in Sophora flavescens, through enzyme treatment. The enzyme-converted Sophora flavescens extract was also found to have hair root strengthening, hair growth promotion, and hair loss mitigation effects.

[0018] According to one aspect of the present invention, the present invention provides a method for producing an enzyme-converted ginseng extract, comprising the following steps:

[0019] (a) a step of obtaining a ginseng extract from dried ginseng; and

[0020] (b) A step of producing an enzyme-converted ginseng extract by performing a hydrolysis reaction through enzyme treatment on the ginseng extract obtained in the above step (a).

[0021] In this specification, the term "Sophora flavescens" refers to a perennial plant of the legume family in the rose order that is native to Asia, including Korea, Japan, and China. In oriental medicine, Sophora flavescens refers to the dried root with the pericarp mostly peeled off. Because of the appearance of the root, Sophora flavescens also has a botanical name, "thief's cane," but the name "Gosam" uses the character "go" because the root of this plant tastes bitter, and the character "sam" because it is said to have the same efficacy as ginseng. The main components of Sophora flavescens are known to be quinolizidine, alkaloid, flavonoid, and saponin, and it is known to have pharmacological effects such as anti-arrhythmic, anti-tumor, diuretic, and antipyretic effects, and it is known to have antibacterial and antifungal effects on skin flora, and is also effective against neurodermatitis and eczema.

[0022] The term "extract" as used herein refers to a result obtained by immersing a target substance in various solvents and then extracting it for a certain period of time at room temperature or at a temperature of 100°C, such as a liquid component, or a solid component obtained by removing the solvent from the liquid component. In addition to the result, the extract may be interpreted to include a dilution of the result, a concentrate thereof, a controlled substance thereof, a purified substance, etc. Accordingly, in the present invention, the extract may be interpreted to include an extract obtained by extraction treatment, a dilution or concentrate of the extract, a dried product obtained by drying the extract, a controlled substance or purified substance of the extract, or a mixture thereof, and an extract of all formulations that can be formed using the extract.

[0023] In the present invention, the extraction method of the extract is not particularly limited, and extraction can be performed according to a method commonly used in the relevant technical field. Non-limiting examples of the extraction method include hot water extraction, solvent extraction, high-frequency extraction, filtration, and reflux extraction, and these may be performed alone or in combination of two or more methods.

[0024] In addition, in the present invention, the type of solvent used for the extraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent include water, alcohol, or a mixed solvent thereof, and these may be used alone or in combination of one or more types. Specifically, water may be used. When alcohol is used as the solvent, an alcohol having 1 to 4 carbon atoms may be used.

[0025] In one embodiment of the present invention, in step (a), the ginseng extract can be obtained by extracting dried ginseng with water, C2-C4 alcohol or a mixed solvent thereof.

[0026] Specifically, the solvent may be a 20-40% (w / w) ethanol aqueous solution.

[0027] The above-mentioned Gosam extract can be used as a component of a composition without a separate additional process after being extracted with ethanol. However, in order to increase the content of effective active ingredients in the Gosam extract, a separate process can be added to the simple Gosam extract obtained through the extraction process.

[0028] In this regard, the present invention provides a method for producing an enzyme-converted soybean extract, and is specifically characterized by providing an enzyme-converted soybean extract produced through a step (b) of performing a hydrolysis reaction by treating the soybean extract obtained through the extraction process of step (a) with an enzyme.

[0029] The term “enzyme-converted ginseng extract” in this specification refers to a ginseng extract obtained through a hydrolysis reaction by treating with a specific enzyme in the step (b).

[0030] Specifically, in one embodiment of the present invention, the enzyme may be one or more enzymes selected from the group consisting of cellulase, hemicellulase, pectinase, arabinase, xylanase, and glucanase, but is not limited thereto. Preferably, the enzyme of step (b) may be one or more enzymes selected from the group consisting of cellulase, hemicellulase, and pectinase.

[0031] In the present invention, the soybean extract obtained through a hydrolysis reaction by treating with an enzyme, specifically, the enzyme-converted soybean extract, is characterized in that it contains a higher content of effective ingredients than a simple soybean extract (untreated soybean extract).

[0032] In one embodiment of the present invention, the ginseng extract or enzyme-converted ginseng extract of the present invention contains trifolirhizin as an active ingredient.

[0033] In one specific example of the present invention, the enzyme-converted ginseng extract is characterized by having a trifolirhizin content that is 1.5 times higher than that of an enzyme-untreated ginseng extract.

[0034] Accordingly, the present invention is characterized in that, in the step (b), the enzyme-converted sophora chinensis extract is treated with at least one enzyme selected from the group consisting of cellulase, hemicellulase, pectinase, arabinase, xylanase, and glucanase, preferably at least one enzyme selected from the group consisting of cellulase, hemicellulase, and pectinase, thereby providing an enzyme-converted sophora chinensis extract in which the content of trifolirhizin, which is an effective ingredient of the sophora chinensis extract, is increased by about 1.5 times or more.

[0035] The increase in the content of trifolirhizin, which is an effective ingredient of the enzyme-converted soybean extract of the present invention, can be understood as a result of trifolirhizin-6'-malonate in the soybean extract being converted into trifolirhizin through a hydrolysis reaction by treatment with the above-described specific enzyme.

[0036] As described above, the ginseng extract of the present invention contains trifolirhizin as an active ingredient. Specifically, in one embodiment of the present invention, the active ingredient is characterized by being trifolirhizin represented by the following chemical formula 1.

[0037] [Chemical Formula 1]

[0038]

[0039] In one embodiment of the present invention, the enzyme-converted ginseng extract is characterized in that it contains trifolirhizin represented by the above-described chemical formula 1 in an amount of 0.05 to 1% (w / w) of the total weight of the extract.

[0040] The above "trifolirhizin" is one of the active ingredients in the Sophora japonica extract, is a derivative of isoflavonoid, and refers to a compound belonging to the organic compound series known as pterocarpans. It is also known as Maackiain 3-glucoside, rifolirhizin, and sophojsophojapo B1, and can be represented by the chemical formula 1 of the compound name of (6aR,12aR)-6a,12a-dihydro-6H-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-yl beta-D-glucopyranoside. In terms of functionality, trifolirhizin is known to have anti-inflammatory and anti-apoptotic effects.

[0041] In the above step (b), the step of performing a hydrolysis reaction by treating the ginseng extract with a specific enzyme may be performed under specific conditions (e.g., pH, reaction time, etc.).

[0042] Specifically, in one embodiment of the present invention, step (b) is characterized in that it is performed at a pH of 3 to 7. Specifically, step (b) may be pH 3 to 7, pH 3 to 6, pH 3 to 5, pH 3 to 4, pH 4 to 7, pH 4 to 6, pH 4 to 5, pH 5 to 7, pH 5 to 6, or pH 6 to 7, but is not limited thereto, and preferably, step (b) may be performed at pH 5.

[0043] In one embodiment of the present invention, the step (b) is characterized in that it is performed for 50 to 80 hours. Specifically, the step (b) may be performed for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, 50 to 55 hours, 55 to 80 hours, 55 to 75 hours, 55 to 70 hours, 55 to 65 hours, 55 to 60 hours, 60 to 80 hours, 60 to 75 hours, 60 to 70 hours, 60 to 65 hours, 65 to 80 hours, 65 to 75 hours, or 65 to 70 hours, but is not limited thereto. Preferably, step (b) may be performed for 65 to 70 hours, and more preferably, step (b) may be performed for 69 hours.

[0044] Specifically, in one embodiment of the present invention, step (b) is characterized in that it is performed at pH 3 to 7 for 50 to 80 hours. More specifically, the step (b) may be performed at a pH of 3 to 7 for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, 50 to 55 hours, 55 to 80 hours, 55 to 75 hours, 55 to 70 hours, 55 to 65 hours, 55 to 60 hours, 60 to 80 hours, 60 to 75 hours, 60 to 70 hours, 60 to 65 hours, 65 to 80 hours, 65 to 75 hours, or 65 to 70 hours, and at a pH of 3 to 6 for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, It may be performed for 50 to 55 hours, 55 to 80 hours, 55 to 75 hours, 55 to 70 hours, 55 to 65 hours, 55 to 60 hours, 60 to 80 hours, 60 to 75 hours, 60 to 70 hours, 60 to 65 hours, 65 to 80 hours, 65 to 75 hours, or 65 to 70 hours, and at pH 3 to 5, for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, 50 to 55 hours, 55 to 80 hours, 55 to 75 hours, 55 to 70 hours, 55 to 65 hours, 55 to 60 hours, It may be performed for 60 to 80 hours, 60 to 75 hours, 60 to 70 hours, 60 to 65 hours, 65 to 80 hours, 65 to 75 hours, or 65 to 70 hours, and may be performed for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, 50 to 55 hours at pH 3 to 4.It may be performed for 55 hours to 80 hours, 55 hours to 75 hours, 55 hours to 70 hours, 55 hours to 65 hours, 55 hours to 60 hours, 60 hours to 80 hours, 60 hours to 75 hours, 60 hours to 70 hours, 60 hours to 65 hours, 65 hours to 80 hours, 65 hours to 75 hours, or 65 hours to 70 hours, and at a pH of 4 to 7, for 50 hours to 75 hours, 50 hours to 70 hours, 50 hours to 65 hours, 50 hours to 60 hours, 50 hours to 55 hours, 55 hours to 80 hours, 55 hours to 75 hours, 55 hours to 70 hours, 55 hours to 65 hours, 55 hours to 60 hours, 60 hours to It may be performed for 80 hours, 60 hours to 75 hours, 60 hours to 70 hours, 60 hours to 65 hours, 65 hours to 80 hours, 65 hours to 75 hours, or 65 hours to 70 hours, and may be performed at a pH of 4 to 6 for 50 hours to 75 hours, 50 hours to 70 hours, 50 hours to 65 hours, 50 hours to 60 hours, 50 hours to 55 hours, 55 hours to 80 hours, 55 hours to 75 hours, 55 hours to 70 hours, 55 hours to 65 hours, 55 hours to 60 hours, 60 hours to 80 hours, 60 hours to 75 hours, 60 hours to 70 hours, 60 hours to 65 hours, 65 hours to 80 hours, 65 hours to 75 hours, or 65 hours to It may be performed for 70 hours, and may be performed at pH 4 to 5 for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, 50 to 55 hours, 55 to 80 hours, 55 to 75 hours, 55 to 70 hours, 55 to 65 hours, 55 to 60 hours, 60 to 80 hours, 60 to 75 hours, 60 to 70 hours, 60 to 65 hours, 65 to 80 hours, 65 to 75 hours, or 65 to 70 hours,It may be performed at pH 5 to 7 for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, 50 to 55 hours, 55 to 80 hours, 55 to 75 hours, 55 to 70 hours, 55 to 65 hours, 55 to 60 hours, 60 to 80 hours, 60 to 75 hours, 60 to 70 hours, 60 to 65 hours, 65 to 80 hours, 65 to 75 hours, or 65 to 70 hours, and at pH 5 to 6 for 50 to 75 hours, 50 to 70 hours, 50 to 65 hours, 50 to 60 hours, 50 to 55 hours, It may be performed for 55 hours to 80 hours, 55 hours to 75 hours, 55 hours to 70 hours, 55 hours to 65 hours, 55 hours to 60 hours, 60 hours to 80 hours, 60 hours to 75 hours, 60 hours to 70 hours, 60 hours to 65 hours, 65 hours to 80 hours, 65 hours to 75 hours, or 65 hours to 70 hours, or at pH 6 to 7 for 50 hours to 75 hours, 50 hours to 70 hours, 50 hours to 65 hours, 50 hours to 60 hours, 50 hours to 55 hours, 55 hours to 80 hours, 55 hours to 75 hours, 55 hours to 70 hours, 55 hours to 65 hours, 55 hours to 60 hours, 60 hours to 80 hours, It may be performed for 60 to 75 hours, 60 to 70 hours, 60 to 65 hours, 65 to 80 hours, 65 to 75 hours, or 65 to 70 hours, but is not limited thereto. Preferably, the step (b) may be performed at pH 5 for 65 to 70 hours, and more preferably, the step (b) may be performed at pH 5 for 69 hours.

[0045] Therefore, in one specific example of the present invention, by treating the above-described specific enzyme on the soybean extract obtained from soybean and performing a hydrolysis reaction at pH 3 to 7 for 50 to 80 hours, preferably at pH 5 for 69 hours, an enzyme-converted soybean extract having a trifolirhizin content increased by about 1.5 times or more compared to an enzyme-untreated soybean extract can be provided.

[0046] Meanwhile, in one embodiment of the present invention, the method for producing an enzyme-converted ginseng extract of the present invention may additionally include a step (c) of encapsulating the enzyme-converted ginseng extract by adding β-cyclodextrin (β-CD) after the step (b).

[0047] That is, in one specific embodiment of the present invention, the present invention provides a method for producing an enzyme-converted ginseng extract comprising the following steps:

[0048] (a) a step of obtaining a ginseng extract from dried ginseng;

[0049] (b) a step of performing a hydrolysis reaction by enzyme treatment on the ginseng extract obtained in the above step (a) to produce an enzyme-converted ginseng extract; and

[0050] (c) a step of mixing beta-cyclodextrin (β-CD) into the above result and encapsulating the enzyme-converted ginseng extract;

[0051] Here, the enzyme of the above step (b) is at least one enzyme selected from the group consisting of cellulase, hemicellulase, and pectinase,

[0052] The above enzyme treatment is characterized by increasing the content of effective ingredients in the extract of red ginseng.

[0053] The above "β-cyclodextrin (β-CD)" refers to a cyclic structure in which glucopyranose molecules are bonded to α-1,4-glycosidic bonds, which are maltooligosaccharides obtained by decomposing starch with CGT-ase (cycloamylose glucanotransferase). This cyclic structure exhibits hydrophilicity on the outside and hydrophobicity on the inside due to the structural characteristics of having only CH and glucoside oxygen, so it can form an inclusion complex by encapsulating various hydrophobic compounds with unstable structures within the hydrophobic cavity. Such inclusion complexes can be utilized in various industrial fields, and among them, β-CD is structurally stable and inexpensive, so it is widely applied in the pharmaceutical, food, and cosmetic industries.

[0054] In one specific example of the present invention, by adding a step of encapsulating the enzyme-converted ginseng extract with beta-cyclodextrin (β-CD) after step (b), the encapsulated ginseng extract can have higher safety in terms of toxicity compared to the ginseng extract before encapsulation.

[0055] In addition, in one specific example of the present invention, the enzyme-converted soybean extract of the present invention can be encapsulated by treating beta-cyclodextrin (β-CD) at various composition ratios, and the solubility of the enzyme-converted soybean extract can be increased due to encapsulation by β-CD. As a specific example, the enzyme-converted soybean extract can exhibit the highest solubility in water at a β-CD mixing ratio of 30% to 70%.

[0056] That is, by further performing step (c) of encapsulating the enzyme-treated soybean extract by adding beta-cyclodextrin (β-CD) after step (b), the enzyme-converted soybean extract has high safety, and also has excellent solubility, suggesting high potential for future use of the enzyme-converted soybean extract.

[0057]

[0058] According to another aspect of the present invention, the present invention provides a hair cosmetic composition for strengthening hair roots, promoting hair growth, or alleviating hair loss, comprising the enzyme-converted ginseng extract of the present invention as an active ingredient.

[0059] Specifically, the present invention provides a hair cosmetic composition for strengthening hair roots, promoting hair growth, or alleviating hair loss, which comprises an enzyme-converted ginseng extract prepared by the method for preparing an enzyme-converted ginseng extract of the present invention as an active ingredient.

[0060] In one embodiment of the present invention, the enzyme may be one or more enzymes selected from the group consisting of cellulase, hemicellulase, pectinase, arabinase, xylanase, and glucanase, but is not limited thereto. Preferably, the enzyme may be one or more enzymes selected from the group consisting of cellulase, hemicellulase, and pectinase.

[0061] In another embodiment of the present invention, the enzyme-converted ginseng extract is characterized in that it is encapsulated by additionally adding beta-cyclodextrin (β-CD).

[0062] The ginseng extract of the present invention contains trifolirhizin as an active ingredient. Specifically, in one embodiment of the present invention, the active ingredient is characterized by being trifolirhizin represented by the following chemical formula 1.

[0063] [Chemical Formula 1]

[0064]

[0065] In one embodiment of the present invention, the enzyme-converted ginseng extract is characterized in that it contains trifolirhizin represented by the chemical formula 1 in an amount of 0.05 to 1% (w / w) of the total weight of the extract.

[0066] In another embodiment of the present invention, the enzyme-converted ginseng extract is characterized by having an increased trifolirhizin content compared to before enzyme treatment.

[0067]

[0068] Recently, various research institutes have been actively conducting research on many regulatory factors involved in hair growth and hair loss mechanisms, and in particular, research on hair growth effects using various factors and their receptors related to the hair cycle of growth, regression, and resting phases has been continuously reported.

[0069] In this regard, in the examples in this specification, the enzyme-converted ginseng extract of the present invention was treated to hair follicle cells, and changes in the expression levels of many regulatory factors involved in hair growth and hair loss mechanisms in hair follicle cells were confirmed accordingly.

[0070] As used herein, the term "hair root cell" refers to all cells present in the root of a hair. Generally, hair can be broadly divided into two regions: the hair shaft (the large stem of the hair), which is the part that extends outside the scalp and can be seen with the naked eye, and the hair root (the root of the hair), which is the part within the scalp. In particular, the hair root is composed of a hair follicle, germinal matrix cells, hair bulb, dermal papilla, etc., and therefore, the term "hair root cell" as used herein may include all cells that form the hair root.

[0071] Specifically, the above “hair root cell” may include dermal papilla cells, germinal matrix cells, etc.

[0072] It is known that the hair papilla cells composed of mesenchymal cells and the hair follicle matrices composed of epithelial cells play a central role in the formation and growth of hair. The hair papilla cells are cells that come out of the dermal cell layer and exist below the hair follicle, that is, in the lowest layer of the hair root. They have many capillaries and autonomic nerves distributed thereto, and supply various nutrients, protein synthesis enzymes, hormones, and oxygen therefrom, thereby controlling hair growth and the hair follicle cycle. The hair matrices are cells that come into contact with the hair papilla, and they continuously repeat division and proliferation using the nutrients and oxygen supplied from the hair papilla, and are characterized by producing keratin protein, the main component of hair, to produce hair.

[0073] Growth factors that affect hair growth in the above hair follicle cells include EGF, EGFF, VEGF, EGFR, HGF / SF, c-MET, FGF, FGFR, IGF, IGF-IR, TGF-β, and TGF-βR, and these are known to affect the hair cycle by regulating the activity of hair follicle cells, specifically, hair papillae, or hair follicle cells surrounding the hair papillae.

[0074] In one embodiment of the present invention, the enzyme-converted soybean extract is characterized in that, when treated on hair root cells, it increases the expression level of genes involved in hair growth in hair root cells compared to when treated with an enzyme-untreated soybean extract.

[0075] Specifically, in one embodiment of the present invention, the enzyme-converted soybean extract is characterized in that, when treated on hair follicle cells, it increases the expression level of genes such as VEGF (Vascular Endothelial Growth Factor), IGF-1 (Insulin-like Growth Factor 1), or a combination thereof in hair follicle cells compared to when treated with an enzyme-untreated soybean extract.

[0076] Meanwhile, scalp inflammation, which causes chronic telogen effluvium, is caused by excessive activation of inflammatory cells, leading to hair loss phenomena such as alopecia areata, which can occur in both men and women of all ages. In particular, infiltration of scalp tissue by T cells, which induce autoimmune inflammation, and the inflammatory factors secreted from these cells are known to play a key role in controlling hair loss. These inflammatory factors include inflammatory mediators (e.g., TNF-α, IL-8) or enzymes related to inflammatory mediators and immune cells (e.g., COX-2).

[0077] In another embodiment of the present invention, the enzyme-converted soybean extract is characterized in that, when treated on hair root cells, the expression level of genes related to inflammatory factors in hair root cells is reduced compared to when treated with an enzyme-untreated soybean extract.

[0078] Specifically, in one embodiment of the present invention, the enzyme-converted Sophora japonica extract is characterized in that, when treated on hair follicle cells, the expression level of genes in the hair follicle cells, which are TGF-β2 (Transforming growth factor-beta2), TNF-α (Tumor necrosis factor-α), IL-8 (Interleukin-8), COX-2 (cyclooxygenase 2), or a combination thereof, is reduced compared to when treated with an enzyme-untreated Sophora japonica extract.

[0079] In one embodiment of the present invention, the hair loss may be stress-induced hair loss or hair loss due to inflammation.

[0080] Specifically, in one embodiment of the present invention, the stress-induced hair loss may be hair loss due to increased expression of inflammatory factors induced by socio-environmental stress, but is not limited thereto.

[0081] In addition, in another embodiment of the present invention, the hair loss due to inflammation may be hair loss due to increased expression of an inflammatory factor induced by an environmental hazard such as fine dust, but is not limited thereto.

[0082] In one specific embodiment of the present invention, the enzyme-converted Sophora japonica extract of the present invention can have a positive effect on alleviating hair loss by reducing the expression of proinflammatory cytokines induced by substance P, a neurotransmitter produced from stress responses, etc. More specifically, in one specific embodiment of the present invention, the enzyme-converted Sophora japonica extract reduces the expression of TGF-β2 and TNF-α increased by substance P.

[0083] In addition, in one specific embodiment of the present invention, the enzyme-converted Sophora japonica extract of the present invention can have a positive effect on alleviating hair loss by reducing the inflammatory response in an inflammatory environment induced by particular matter 10, which is a fine dust. More specifically, in one specific embodiment of the present invention, the enzyme-converted Sophora japonica extract reduces the expression of IL-8 and COX-2 increased by particular matter 10.

[0084] Therefore, the enzyme-converted Gosam extract can provide excellent hair root strengthening, hair growth promotion, and hair loss alleviation effects by increasing the expression of the VEGF gene, known as a factor related to hair root strengthening, and the IGF-1 gene, known as a factor related to hair growth, and reducing the expression of the TGF-β2, TNF-α, IL-8, and COX-2 genes, which are factors related to inflammatory reactions that cause stress-induced and fine dust-induced hair loss.

[0085] The components included in the hair cosmetic composition of the present invention may include, in addition to the enzyme-converted ginseng extract as an effective ingredient, components commonly used in hair cosmetic compositions, and include, for example, conventional auxiliary agents and carriers such as stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0086] The above hair cosmetic composition may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these ingredients can be easily selected by a person skilled in the art.

[0087] When the formulation of the hair cosmetic composition of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.

[0088] When the formulation of the hair cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.

[0089] When the formulation of the hair cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used as a carrier component.

[0090] When the formulation of the hair cosmetic composition of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative, or ethoxylated glycerol fatty acid ester may be used as a carrier component.

[0091] When the formulation of the hair cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane-butane or dimethyl ether may be additionally included.

[0092] The enzyme-converted sophora chinensis extract of the present invention may be included in a relatively high concentration in wash-off type cosmetics, such as makeup removers and cleansers, where the active ingredients remain on the skin for a short period of time when manufactured as cosmetics. On the other hand, leave-on type cosmetics, such as toners, emulsions, creams, and essences, where the active ingredients remain on the skin for a long period of time, may include a lower concentration of the enzyme-converted sophora chinensis extract compared to wash-off type cosmetics.

[0093] Inventions according to the above-described other aspects of the present invention share the main structure or technology with the above-described inventions, so that any overlapping content between the two inventions can be equally applied.

[0094]

[0095] When using a hair cosmetic composition containing the enzyme-converted ginseng extract of the present invention as an active ingredient, it is expected to have an excellent hair loss alleviation effect by stimulating hair growth factors to strengthen hair roots and promote hair growth, as well as inhibiting hair loss-inducing factors that promote transition to the hair catagen phase by shortening the hair follicle growth phase and shortening the hair resting phase in an inflammatory environment with anti-inflammatory activity.

[0096]

[0097] Figure 1 shows the results of visually confirming the degree of dissolution of Examples 1 to 4 of the present invention and the amount of sediment.

[0098]

[0099] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0100]

[0101] Example

[0102] Throughout this specification, "%" used to indicate the concentration of a particular substance is (weight / weight) % for solid / solid, (weight / volume) % for solid / liquid, and (volume / volume) % for liquid / liquid, unless otherwise noted.

[0103]

[0104] Manufacturing Example 1. Manufacturing of “Ginseng Extract”

[0105] 100 g of dried Sophora flavescens purchased from Gyeongdong Market in Seoul was thoroughly washed, cut into pieces of 5 cm or less, and then 1000 g of 50% (w / w) ethanol was added and extracted by heating at 60°C for 24 hours. The extract was first filtered through a filter cloth and then secondarily filtered through a 0.5 μm membrane. The filtrate was concentrated under reduced pressure and freeze-dried to obtain Sophora flavescens extract powder.

[0106]

[0107] Example 1. Preparation of “enzyme-converted ginseng extract”

[0108] First, 120 g of purified water was added to 12 g of the concentrated powder of the extract of the ginseng obtained in the above manufacturing example 1, and then a sterilization process was performed in an autoclave (121°C, 15 minutes), and then the enzyme was treated to prepare the enzyme-converted extract of the present invention.

[0109] Specifically, the enzyme is an enzyme commonly used to decompose fruit and vegetable tissues, and Plantase PT (Vision Biochem), a mixed enzyme containing pectinase, cellulase, and hemicellulase in a certain ratio, was used. 10 mg of Plantase PT was added to the sterilized 40°C soybean extract solution, and the enzyme reaction was performed for 69 hours under pH 5 and 60°C conditions. Then, in order to terminate the reaction, the reaction was inactivated by autoclaving (121°C, 15 minutes), and then concentrated under reduced pressure to obtain an enzyme-converted soybean extract powder.

[0110]

[0111]

[0112] Experimental Example 1. Measurement of trifolirhizin content

[0113] In order to compare the content of trifolirhizin in the extract of the above-mentioned manufacturing example 1 and the enzyme-converted extract of the example 1, the content thereof was measured using high-performance liquid chromatography (HPLC).

[0114] The results are shown in Table 1 below.

[0115] Comparison of the content of trifolirhizin in the extract of the ginseng of Manufacturing Example 1 and the enzyme-converted extract of the ginseng of Example 1. Material Manufacturing Example 1 Example 1 Trifolirhizin (㎍ / g) 4,3346,805

[0116]

[0117] As a result of the above measurement, it was confirmed that the enzyme-converted ginseng extract of Example 1 had a higher trifolirhizin content, and specifically, it was confirmed that it contained about 1.5 times more trifolirhizin than the ginseng extract before enzyme treatment of Preparation Example 1.

[0118] Afterwards, in order to increase the stability of trifolirhizin, an effective ingredient in the soybean extract, an additional step of encapsulating the soybean extract by adding β-cyclodextrin (β-CD) to the soybean extract (Preparation Example 1) and the enzyme-converted soybean extract (Example 1) was performed.

[0119]

[0120] Examples 2 to 4. Preparation of “enzyme-converted ginseng extract” encapsulated with β-cyclodextrin (β-CD)

[0121] First, beta-cyclodextrin (β-CD) was added to the enzyme-converted ginseng extract obtained in Example 1, and then completely dissolved in 50% ethanol (w / w), concentrated under reduced pressure, and vacuum-dried to obtain a mixed powder.

[0122] Specifically, in order to optimize the mixing composition ratio of the enzyme-converted soybean extract by encapsulating it with β-CD, β-CD was treated at various composition ratios to obtain a mixed powder, and Table 2 below shows the mixing composition ratio of the enzyme-converted soybean extract and β-CD used in this example.

[0123] Mixed composition ratio powder manufacturing conditions with beta-cyclodextrin (β-CD) Enzyme conversion Sophora japonica extract Beta-cyclodextrin Final mixed powder Example 23g 7g 10g Example 34g 6g 10g Example 45g 5g 10g

[0124]

[0125] Experimental Example 2. Solubility test according to inclusion with β-cyclodextrin (β-CD)

[0126] Using enzyme-converted soybean extracts encapsulated in various mixing ratios with the above-mentioned beta-cyclodextrin (β-CD), the solubility of the enzyme-converted soybean extracts in water according to encapsulation with β-CD was measured.

[0127] The results are shown in Table 3 and Figure 1 below.

[0128] Comparison of the solubility of enzyme-converted sophora japonica extracts encapsulated by β-CD Powder manufacturing conditions Enzyme-converted sophora japonica extract β-cyclodextrin (β-CD) Total powder amount Purified amount Total amount Powder Solubility (%) Example 10.45g 0.0g 0.45g 9.55g 10g 76.0% Example 20.45g 1.05g 1.50g 8.50g 10g 94.3% Example 30.45g 0.675g 1.125g 8.875g 10g 91.9% Example 40.45g 0.45g 0.90g 9.10g 10g 83.8%

[0129]

[0130] As shown in Table 3 above, it was confirmed that the enzyme-converted ginseng extracts (Examples 2 to 4) containing β-CD exhibited better solubility.

[0131] Specifically, it was confirmed that the solubility of the enzyme-converted soybean extract encapsulated with β-CD of Example 2 increased by about 124% or more compared to the enzyme-converted soybean extract (Example 1) that was not encapsulated with β-cyclodextrin (β-CD).

[0132] In addition, it was confirmed that there was a difference in solubility depending on the mixing ratio applied when encapsulating with β-CD, and it was confirmed that the enzyme-converted ginseng extract of Example 2 (encapsulated at a mixing ratio of 3:7) showed the best solubility compared to Examples 3 and 4.

[0133] Accordingly, in all subsequent experiments, the enzyme-converted ginseng extract of Example 2 was used as the experimental group.

[0134]

[0135] Comparative Example 1. Preparation of “Ginseng Extract” Encapsulated with Beta-Cyclodextrin (β-CD)

[0136] In addition, in all subsequent experiments, an untreated soybean extract was used as a control group, and for this purpose, a soybean extract encapsulated with beta-cyclodextrin (β-CD) (Comparative Example 1) was prepared by performing the same method as the manufacturing method of Example 2.

[0137] Specifically, 7 g of beta-cyclodextrin (β-CD) was added to 3 g of the extract of the Korean ginseng obtained in Manufacturing Example 1, and then completely dissolved in 30 g of 50% ethanol (w / w), concentrated under reduced pressure, and vacuum-dried to obtain a mixed powder.

[0138]

[0139] Experimental Example 3. Cytotoxicity Evaluation

[0140] The cytotoxicity evaluation of Comparative Example 1 and Example 2 was performed using HDPs (Human Hair Follicle Dermal Papilla Cells) and HHGMCs (Human Hair Germinal Matrix Cells).

[0141] Cell viability was measured using the WST-1 assay. This method measures cell viability using formazan, a chromogenic substance formed by the reaction between mitochondrial dehydrogenase and a water-soluble tetrazolium salt within the cell.

[0142] In this example, specific cytotoxicity evaluation was performed as follows:

[0143] The above two cell lines (HDPs cell line, HHGMCs cell line) were cultured at 6x10 4Inoculate into a 48-well plate at a concentration of 10 cells / ml and culture for 24 hours. Then, replace with CEFOgro™ Human Dermal Papilla Growth Medium and mesenchymal stem cell medium (MSCM) without added FBS, treat with the experimental substances at various concentrations, and culture for 24 hours. After culture, replace the WST-1 solution in the cells with a solution diluted 10-fold in CEFOgro™ Human Dermal Papilla Growth Medium and MSCM, incubate for 1 hour at 37°C, and measure the absorbance at 450 nm using an ELISA reader.

[0144] The cell viability was calculated using the following experimental formula 1, and the expression level in the Control (negative control group / untreated group) was set to 100, and the results for all experimental groups based on this were shown in Tables 4 and 5 below.

[0145] [Experimental Formula 1]

[0146]

[0147]

[0148] Toxicity evaluation in HHGMC cells Sample experiment Concentration Cell viability (%) p-value Average Stdev. Control 100.05.211.000 Trifolirhizin (ppm) 0.0197.06.560.3020.025103.04.380.2040.05100.63.890.7790.197.93.900.3400.25100.15.990.9790.5101.24.040.582 Manufacturing example 1 (ppm)196.44.720.2561096.84.190.27925101.91.560.4745092.03.840.01810018.24.070.000Comparative Example 1 (ppm)197.44.030.1911097.11.330.0632595.22.160.0085094.72.050.00310093.92.670.002Example 1 (ppm)1100.00.741.0001098.82.190.4222598.91.670.3745098.11.930.19010099.01.870.422Example 2 (ppm)197.86.310.3961098.46.400.5482596.44.520.0975096.78.890.33110097.97.550.467Example 3 (ppm)199.23.240.77510104.23.080.16225100.04.610.9925099.95.920.97210074.14.410.000Example 4 (ppm)199.23.240.7751096.72.530.1142590.37.910.0405070.33.920.00010095.57.380.245

[0149]

[0150] First, as shown in Table 2 above, it was confirmed that the ginseng extract (Comparative Example 1) encapsulated with beta-cyclodextrin (β-CD) had much better cell viability than the ginseng extract before encapsulation (Preparation Example 1).

[0151] Through this, it was confirmed that the use of the ginseng extract of the present invention is safer in terms of toxicity by adding a step of encapsulating the ginseng extract with β-CD.

[0152] However, it was confirmed that the enzyme-converted extract of the enzyme-treated ginseng showed excellent safety in terms of toxicity due to the enzyme conversion, regardless of inclusion by β-CD.

[0153]

[0154] Therefore, in all subsequent experiments, the β-CD-conjugated ginseng extract was used. Specifically, the (untreated) ginseng extract of Comparative Example 1 was used as a control group, and the enzyme-converted ginseng extract of Example 2 was used as an experimental group.

[0155]

[0156] Toxicity evaluation in HDP cells Sample experiment Concentration Cell viability (%) p-value Average Stdev. Control 100.09.06 1.000 Trifolirhizin (ppm) 0.01 10 1.88.95 0.67 70.025 10 1.51 0.99 0.76 30.05 9 9.88.64 0.95 9 0.19 8.28 11 0.66 10.25 9 7.68.99 0.57 30.59 4.19 31 0.190 Comparative example 1 (ppm)1103.93.980.0885101.86.990.54810101.44.270.53925100.74.020.7625097.41.880.17510097.12.070.141Example 2 (ppm)1105.85.930.0675104.76.880.15510101.48.080.70025101.17.830.74750102.66.330.413100103.28.210.369

[0157]

[0158] As shown in Tables 4 and 5 above, based on the toxicity evaluation results in each cell, the concentrations of the test substances to be used in subsequent experiments were determined. Specifically, in the case of trifolirhizin, the concentrations were determined to be 0.025, 0.05, and 0.1 ppm, and in the case of Comparative Example 1 (Sophora japonica extract before enzyme treatment + β-CD) and Example 2 (Sophora japonica extract converted to enzyme + β-CD), the concentrations were determined to be 25, 50, and 100 ppm.

[0159] Accordingly, in evaluating the expression pattern of hair-related genes in each cell, the substance concentration determined from the cytotoxicity evaluation was used.

[0160]

[0161] Experimental Example 4. Evaluation of changes in hair-related gene expression levels due to enzyme-converted soybean extract.

[0162] In order to confirm the effect of strengthening hair roots and increasing hair growth by the enzyme-converted ginseng extract captured by treating the β-CD of Example 2 above, and the effect of alleviating hair loss caused by stress or environmental hazards (e.g., fine dust), the changes in the expression levels of hair-related genes caused by the experimental substances were compared and analyzed.

[0163]

[0164] Experimental Example 4.1. Cell Culture

[0165] First, the HDPs cell line was cultured using CEFOgro™ Human Dermal Papilla Growth Medium supplemented with 4% CEFOgro™ Human Dermal Papilla Growth Medium Supplement (CEPOgro-HDP-SP, Cell Bio) and 0.5% Penicillin / streptomycin solution (Cell Bio), and the HHGMCs cell line was cultured using MSCM (Mesenchymal Stem Cell Medium) containing 5% FBS, 1% penicillin / streptomycin solution (S / P), and 1% mesenchymal stem cell growth supplement (MSCGS) at 37°C under 5% CO2 conditions.

[0166] Next, the cells for the experiment were prepared by culturing the HDPs cell line with CEFOgro™ Human Dermal Papilla Growth Medium containing FBS, or the HHGMCs cell line with MSCM containing 5% FBS in a 6-well multi plate for 24 hours, and then replacing each well with serum-free medium.

[0167] i) To confirm the hair growth effect, HHGMCs cells were treated with the experimental substance and cultured for 48 hours; ii) To confirm the hair root strengthening effect, HDPs cells were treated with the test sample and cultured for 24 hours; iii) To confirm the stress-induced hair loss alleviation effect, HDPs cells were treated with Substance P, Acetate salt hydrate (Sigma aldrich, S6883), which is secreted when stress occurs, and the experimental substance and cultured for 16 hours; and iv) To induce hair loss conditions due to environmental hazards, HHGMCs cells were treated with particular matter 2.5 (ERMCZ110, Sigma-Aldrich, Germany), which is a fine dust, and the experimental substance and cultured for 24 hours. The experimental substances used in Comparative Example 1 and Example 2 were used, and caffeine (C0750, Sigma-Aldrich) and adenosine (A4036, Sigma-Aldrich) were used as positive controls.

[0168]

[0169] Experimental Example 4.2. qRT-PCR

[0170] First, each cell treated with the experimental substance was washed with PBS (Phosphate-buffered saline) after each treatment time. Next, to analyze the expression level of hair-related genes, total RNA was extracted using QIAzol Lysis Reagent (QIAGEN) according to the manufacturer's instructions. The isolated RNA was quantified using a Qubit™ fluorometer with RNA BR Assay kit, and then cDNA was synthesized and real-time PCR was performed. The cDNA synthesis was performed using the qPCRBIO cDNA Synthesis Kit according to the kit's instructions, and real-time PCR (QST 7500 Fast Real Time, Applied Biosystems™) was performed using 2x qPCRBIO SyGreen Blue mix Lo-ROX. In addition, gene expression was quantitatively measured using the primers presented in Table 6 below, and the relative values ​​normalized to β-actin were compared and analyzed.

[0171] Primer information for evaluating hair-related gene expressionPrimersenseantisenseIGF-15'-AGC CTG TCC ACC CTT GAG AA-3'5'-CCC TGG AGC CAC AGA GCA T-3'VEGF5'-TGC AGA TTA TGC GGA TCA AAC C-3'5'-TGC ATT CAC ATT TGT TGT GCT GTA G-3'TGF-β25'-CAC CAT AAA GAC AGG AAC CTG-3'5'-GGA GGT GCC ATC AAT ACC TGC-3'TNF-α5'-CCC AGG GAC CTC TCT CTA ATC-3'5'-GGT TTG CTA CAA CAT GGG CTA CA-3'IL-85'-CTG GCC GTG GCT CTC TTG-3'5'-CCT TGG CAA AAC TGC ACC TT-3'COX-25'-CTG AAG CCC ACC CCA AAC A-3'5'-AAC CCA GGT CCT CGC TTA TG-3'β-actin(control)5'-GGC ACC CAG CAC AAT GAA G-3'5'-CCG ATC CAC ACG GAG TAC TTG-3'

[0172]

[0173] Comparative Example 4.3. Hair Growth Effect Experiment

[0174] : Evaluation of IGF-I (Insulin-like Growth Factor) gene expression

[0175] To confirm the hair growth effect of the enzyme-converted Gosam extract of the present invention, qRT-PCR was performed using HHGMCs cells to compare and analyze the expression level of the IGF-I (Insulin-like Growth Factor) gene. 5 ppm of caffeine was also used as a positive control.

[0176] The results are shown in Table 7 below.

[0177] Comparative analysis of the expression level of IGF-1 gene according to experimental substance treatment group and treatment concentration Sample Experimental concentration IGF-1 mRNA expression (%) p-value Average Stdev. Control group (control) 100.000.001.000 Caffeine (ppm) 5135.57.390.000 Trifolirhizin (ppm) 0.02594.210.700.1230.05116.79.420.0000.1127.89.900.000 Comparative example 1 (ppm) 25111.23.760.00050125.33.880.000100135.82.610.000 Example 2 (ppm)25116.14.840.00050131.87.140.000100144.95.780.000

[0178]

[0179] As shown in Table 7 above, the expression level in the Control was set to 100, and the expression levels of the IGF-1 gene in all experimental groups were compared based on this. As a result, it was confirmed that the expression of the IGF-1 gene increased as the treatment concentration of the experimental substance (trifolirhizin, Comparative Example 1, and Example 2) increased in all experimental groups.

[0180] In particular, when Comparative Example 1 and Example 2, which are Sophora japonica extracts as experimental materials, were treated, the IGF-1 gene expression was shown to be more increased than in the group treated with trifolirhizin (single substance), and it was confirmed that the group treated with Example 2 (enzyme-converted Sophora japonica extract) showed a higher IGF-1 gene expression value than the group treated with Comparative Example 1 (Sophora japonica extract before enzyme treatment).

[0181] Thus, it was confirmed that the enzyme-converted ginseng extract (Example 2) obtained through an enzymatic reaction has a hair growth effect by increasing the expression of the IGF-1 gene, which is an insulin-like growth factor.

[0182]

[0183] Comparative Example 4.4. Experiment on hair root strengthening effect

[0184] : Evaluation of VEGF (Vascular Endothelial Growth Factor) gene expression

[0185] To confirm the root strengthening effect of the enzyme-converted Sophora japonica extract of the present invention, qRT-PCR was performed using HDPs cells to compare and analyze the expression level of the VEGF (Vascular Endothelial Growth Factor) gene, a vascular endothelial growth factor. 0.75 mM adenosine was also used as a positive control.

[0186] The results are shown in Table 8 below.

[0187] Comparative analysis of the expression level of VEGF gene according to experimental substance treatment group and treatment concentration Sample Experimental concentration VEGF mRNA expression (%) p-value Average Stdev. Control group (control) 100.000.001.000 Adenosine (mM) 0.75 199.09.910.000 Trifolirhizin (ppm) 0.025 93.42.150.0000.05 100.83.320.5050.1111.72.920.000 Comparative example 1 (ppm) 25 117.23.260.00050142.55.770.000100190.24.480.000 Example 2 (ppm)25122.07.150.00050165.212.100.000100253.221.650.000

[0188]

[0189] As shown in Table 8 above, the expression level in the Control was set to 100, and the expression levels of the VEGF gene in all experimental groups were compared based on this. As a result, it was confirmed that the expression of the VEGF gene increased as the treatment concentration of the experimental substance (trifolirhizin, Comparative Example 1, and Example 2) increased in all experimental groups.

[0190] In particular, in the case of Comparative Example 1 and Example 2 using the Sophora japonica extract as the experimental material, VEGF gene expression was increased compared to when trifolirhizin (single substance) was treated, and VEGF gene expression was higher in Example 2, which is an enzyme-converted Sophora japonica extract, than in Comparative Example 1, which is a Sophora japonica extract before enzyme treatment.

[0191] Accordingly, it was confirmed that the enzyme-converted extract of Gosam (Example 2) captured as β-cyclodextrin (β-CD) through an enzymatic reaction had a hair root strengthening effect by increasing the expression of the VEGF gene, which is a vascular endothelial cell growth factor.

[0192]

[0193] Comparative Example 4.5. Stress-induced hair loss relief experiment

[0194] : Evaluation of expression of TGF-β2 (Transforming growth factor-beta2) and TNF-α (Tumor necrosis factor-α) genes

[0195] In order to confirm the effect of the enzyme-converted Sophora japonica extract of the present invention on alleviating hair loss symptoms caused by stress, qRT-PCR was performed using HDP cells to compare and analyze the expression levels of TGF-β2 (Transforming growth factor-beta2) and TNF-α (Tumor necrosis factor-α) genes, which are hair loss and inflammation-inducing factors. In addition, for stress-induced hair loss conditions, Substance P (SP), Acetate salt hydrate (SP) (Sigma aldrich, S6883), which is secreted when stress occurs, was treated together with the experimental substances, and then the experiment was performed. 5 ppm of caffeine was also used as a positive control.

[0196] The results are shown in Tables 9 and 10 below.

[0197] Comparison of the expression level of TGF-β2 gene according to experimental substance treatment group and treatment concentration Analysis sample Experimental concentration TGF-β2 mRNA expression (%) p-value Average Stdev. Control group (control) 67.9 3.39 1.000 Substance P (nM) 2.5 100.00.000.000 SP + Caffeine (ppm) 577.14.9 10.000 SP + Tripolylysine (ppm) 0.02 587.13.69 0.0000.05 89.43.4 10.0000.16 1.89.7 10.000 SP + Comparative Example 1 (ppm) 2587.5 2.75 0.000 508 0.02.5 10.000 100 76.6 2.19 0.000 SP + Example 2 (ppm)2582.52.700.0005073.63.070.00010070.02.710.000

[0198]

[0199] First, as shown in Table 9 above, the expression level in the SP only treatment group was set to 100, and the expression levels of the TGF-β2 gene in all experimental groups were compared based on this, and it was confirmed that the expression of the TGF-β2 gene decreased in all experimental groups.

[0200] Specifically, it was confirmed that all experimental material (trifolirhizin, Comparative Example 1, and Example 2) treatment groups showed low TGF-β2 gene expression patterns like the control group (SP untreated group / positive control group) under stress conditions, thereby confirming that the Sophora japonica extract and trifolirhizin, an effective ingredient in the Sophora japonica extract, can alleviate hair loss caused by stress by suppressing the expression of TGF-β2.

[0201]

[0202] Comparison of the expression level of TNF-α gene according to the experimental substance treatment group and treatment concentration Analysis sample Experimental concentration TNF-α mRNA expression (%) p-value Average Stdev. Control group (control) 51.66.360.000 substance P (nM) 2.5100.00.001.000 SP + caffeine (ppm) 561.94.000.000 SP + tripolylysine (ppm) 0.02591.66.110.0010.0589.58.240.0020.158.79.490.000 SP + Comparative Example 1 (ppm) 2574.83.590.0005060.02.380.00010061.22.140.000 SP + Example 2 (ppm)2565.74.710.0005045.73.290.00010055.14.550.000

[0203]

[0204] In addition, as shown in Table 10 above, the expression level in the SP only treatment group was set to 100, and when the expression level of the TNF-α gene in all experimental groups was compared based on this, it was confirmed that the expression of TNF-α decreased in all experimental groups.

[0205] Specifically, it was confirmed that all experimental material (trifolirhizin, comparative example 1, and example 2) treatment groups showed a low expression of TNF-α gene under stress conditions, similar to the control (SP untreated group / positive control group), thereby confirming that the Sophora japonica extract and trifolirhizin, an effective ingredient in the Sophora japonica extract, can suppress the expression of TNF-α and alleviate hair loss caused by stress.

[0206] In particular, it was confirmed that the group treated with 50 ppm of Example 2 (enzyme-converted ginseng extract) showed a lower TNF-α expression pattern than all experimental substance treatment groups except the control group.

[0207]

[0208] Comparative Example 4.6. Experiment on the Alleviation of Hair Loss Caused by Environmental Harmful Factors

[0209] : Evaluation of expression of IL-8 (Interleukin-8) and COX-2 (cyclooxygenase 2) genes

[0210] Environmental pollutants such as fine dust in the air are reported to be one of the main causes of hair loss symptoms, and these hair loss symptoms are closely related to scalp inflammation caused by environmental pollutants.

[0211] This example was conducted to confirm the effect of the enzyme-converted Sophora japonica extract of the present invention on alleviating hair loss symptoms caused by scalp dermatitis due to exposure to environmental hazards (e.g., fine dust). To this end, qRT-PCR was performed using HHGMCs cells to compare and analyze the expression levels of the IL-8 (Interleukin-8) gene and COX-2 (cyclooxygenase 2) gene, which are inflammatory response factors. As an environmental hazard that can induce hair loss symptoms caused by scalp dermatitis, the experiment was conducted by treating particular matter 2.5 (PM2.5, ERM-CZ110, Sigma-Aldrich), which is fine dust, together with the test substance. 5 ppm of caffeine was also used as a positive control.

[0212] The results are shown in Tables 11 and 12 below.

[0213] Comparison of the expression level of the IL-8 gene according to the experimental substance treatment group and treatment concentration Analysis sample Experimental concentration IL-8 mRNA expression (%) p-value Average Stdev. Control group (control) 33.6 3.6 30.000 PM 2.5 (ppm) 50 100.00.00 1.000 PM + Caffeine (ppm) 57 2.14.0 80.000 PM + Tripolylysine (ppm) 0.02 57 5.12.8 90.0000.05 74.17.2 90.0000.15 6.76.7 50.000 PM + Comparative Example 1 (ppm) 25 8 5.11.7 10.000 50 77 81.3 0.000 100 67.8 1.1 10.000 PM + Example 2 (ppm)2582.42.320.0005070.74.590.00010060.55.740.000

[0214]

[0215] First, as shown in Table 11 above, the expression level in the PM only treatment group was set as 100, and the expression level of the IL-8 gene in all experimental groups was compared based on this. As a result, it was confirmed that the expression of IL-8 decreased as the treatment concentration of the experimental substance (trifolirhizin, Comparative Example 1, and Example 2) increased in all experimental groups.

[0216] Specifically, it was confirmed that all experimental material (trifolirhizin, comparative example 1, and example 2) treatment groups showed low IL-8 gene expression patterns under fine dust conditions, and although they did not show low levels of IL-8 expression like the control (PM untreated group / positive control group), they showed a decrease of about 40-45% compared to the IL-8 expression level in the PM only treatment group (negative control group), thereby confirming that the Sophora japonica extract and trifolirhizin, an active ingredient in the Sophora japonica extract, can alleviate hair loss caused by fine dust by suppressing the expression of IL-8.

[0217] Comparison of the expression level of COX-2 gene according to experimental substance treatment group and treatment concentration Analysis Sample Experiment Concentration COX-2 mRNA Expression (%) p-value Average Stdev. Control group (control) 4.9 0.8 7 0.000 PM 2.5 (ppm) 50 100.00.00 1.000 PM + Caffeine (ppm) 57 1.5 4.3 3 0.000 PM + Tripolylysine (ppm) 0.02 57 4.23 15 0.0000 05 7 4.15 35 0.0000 15 7.15 56 0.000 PM + Comparative Example 1 (ppm) 25 8 3.02 98 0.000 50 7 2.9 2.6 3 0.000 100 64.21 96 0.000 PM + Example 2 (ppm)2580.32.480.0005066.63.640.00010055.74.140.000

[0218]

[0219] In addition, as shown in Table 12 above, the expression level in the PM only treatment group was set as 100, and the expression level of the COX-2 gene in all experimental groups was compared based on this. As a result, it was confirmed that the expression of COX-2 decreased as the treatment concentration of the experimental substance (trifolirhizin, Comparative Example 1, and Example 2) increased in all experimental groups.

[0220] Specifically, it was confirmed that all experimental substance (trifolirhizin, Comparative Example 1, and Example 2) treatment groups showed low COX-2 gene expression patterns under fine dust conditions, and although they did not show a very low level (4.9%) of COX-2 expression like the Control (PM untreated group / positive control group), it was confirmed that they showed a decrease of about 45% compared to the expression level of COX-2 in the PM only treatment group (negative control group). Accordingly, it was confirmed that the Sophora japonica extract and trifolirhizin, an active ingredient in the Sophora japonica extract, can alleviate hair loss caused by environmental harmful factors such as fine dust by suppressing the expression of COX-2, an inflammatory response factor.

[0221] In particular, it was confirmed that the group treated with 100 ppm of Example 2 (enzyme-converted ginseng extract) showed a lower COX-2 expression pattern than all experimental substance treatment groups except the control.

Claims

1. A method for producing an enzyme-converted ginseng extract comprising the following steps: (a) a step of obtaining a ginseng extract from dried ginseng; and (b) A step of performing a hydrolysis reaction by treating the ginseng extract obtained in the above step (a) with an enzyme.

2. In paragraph 1, A method for producing an enzyme-converted ginseng extract, wherein the enzyme of the above step (b) is at least one enzyme selected from the group consisting of cellulase, hemicellulase, pectinase, arabinase, xylanase, and glucanase.

3. In paragraph 1, A method for producing an enzyme-converted ginseng extract, characterized in that the above step (b) is performed at a pH of 3 to 7.

4. In paragraph 1, A method for producing an enzyme-converted ginseng extract, characterized in that the above step (b) is performed for 50 to 80 hours.

5. In paragraph 1, A method for producing an enzyme-converted ginseng extract, characterized in that the above step (b) is performed at a pH of 3 to 7 for 50 to 80 hours.

6. A method for producing an enzyme-converted ginseng extract, further comprising a step (c) of encapsulating the enzyme-converted ginseng extract by adding beta-cyclodextrin after step (b) in the first paragraph.

7. A hair cosmetic composition for strengthening hair roots, promoting hair growth, or alleviating hair loss, containing enzyme-converted ginseng extract as an active ingredient.

8. A hair cosmetic composition according to claim 7, wherein the enzyme is at least one enzyme selected from the group consisting of cellulase, hemicellulase, pectinase, arabinase, xylanase, and glucanase.

9. A hair cosmetic composition according to claim 7, characterized in that the enzyme-converted ginseng extract is encapsulated by additionally adding beta-cyclodextrin (β-CD).

10. In the 7th paragraph, the enzyme-converted ginseng extract contains trifolirhizin represented by the following chemical formula 1 in an amount of 0.05% to 1 (w / w) of the total weight of the extract, a hair cosmetic composition: [Chemical Formula 1] .

11. In paragraph 7, A hair cosmetic composition characterized in that the enzyme-converted ginseng extract has an increased trifolirhizin content compared to before enzyme treatment.

12. In paragraph 7, A hair cosmetic composition, wherein the enzyme-converted soybean extract, when treated on hair root cells, increases the expression level of genes such as VEGF (Vascular Endothelial Growth Factor), IGF-1 (Insulin-like Growth Factor 1), or a combination thereof in hair root cells compared to when treated with an enzyme-untreated soybean extract.

13. In paragraph 7, A hair cosmetic composition, wherein the enzyme-converted Sophora japonica extract, when treated on hair root cells, reduces the expression level of genes in hair root cells, such as TGF-β2 (Transforming growth factor-beta2), TNF-α (Tumor necrosis factor-α), IL-8 (Interleukin-8), COX-2 (cyclooxygenase 2), or a combination thereof, compared to when treated with an enzyme-untreated Sophora japonica extract.

14. A hair cosmetic composition according to claim 7, wherein the hair loss is hair loss caused by stress, environmental hazards, or inflammation.

Images